Brief: Dermapharm - Confirms Full-Year Guidance For 2025
Nov 13 (Reuters) - DERMAPHARM HOLDING SE DMPG.DE: 9M EBITDA MARGIN 26.5% 9M REVENUE EUR 869.4 MILLION 9M EBITDA EUR 230.8 MILLION 9M ADJUSTED EBITDA EUR 236 MILLION 9M ADJUSTED EBITDA MARGIN 27.1% CONFIRMS FULL-YEAR GUIDANCE FOR 2025 Source text: ID:nEQ1XpLkwa Further company coverage: DMPG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit